

www.ebmt.org

Paris, June 2nd 2020

Board members

President
Nicolaus Kröger

Secretary
John Snowden

Treasurer
Harry Dolstra

**Scientific Council Chair with
Portfolio Research and Sciences**
Mohamad Mohty

**Scientific Council Vice-Chair with
Portfolio Research and Sciences**
Christian Chabannon

**Scientific Council Representative
with Portfolio Registry**
John Snowden

**Scientific Council Representative
with Portfolio Education**
Grzegorz W. Basak

Nurses Group President
John Murray

EBMT 2020 Annual Meeting President
Rafael Duarte

Scientific Council - Working Party Chairpersons

Acute Leukaemia
Mohamad Mohty

Autoimmune Diseases
Raffaella Greco

Cellular Therapy & Immunobiology
Christian Chabannon

Chronic Malignancies
Ibrahim Yakoub-Agha

Inborn Errors
Arjan Lankester

Infectious Diseases
Rafael de la Camara

Lymphoma
Bertram Glass

Paediatric Diseases
Selim Corbacioglu

Severe Aplastic Anaemia
Régis Peffault de Latour

Transplant Complications
Grzegorz W. Basak

Invitation to participate in EBMT LWP Study 2019-R-05

A Comparison between ATG and PT-CY graft-versus-host-disease prophylaxis in patients with lymphoma undergoing reduced intensity conditioning regimen HSCT from 1 antigen MMUD

Post Transplant-Cyclophosphamide (PT-CY) has been first used for prevention of acute and chronic graft-versus-host-disease (GVHD) in the setting of haploidentical transplantation (HAPLO) almost 10 years ago. Subsequently, different studies have reported promising results with respect to non-relapse mortality (NRM), GVHD and infections for HAPLO PT-CY compared to other donor sources. As a consequence, this platform has also been investigated in the setting of HLA-identical sibling and matched unrelated donor (MUD). To date, two single-center studies have compared outcomes of patients with various hematological malignancies undergoing mismatched unrelated donor (MMUD) with either PT-CY or Anti-thymocyte globulin (ATG) as GVHD prophylaxis in small cohorts. More recently, a matched pair analysis was conducted in AML patients with results indicating lower incidence of grade III-IV acute GVHD and higher LFS for the PT-Cy group. So far, no other studies have compared the use of PT-CY to ATG in the setting of MMUD 9/10 in a homogeneous cohort of lymphoproliferative disorders.

We would like to invite you to participate in this study by providing data from patients undergoing transplantation in your centre. Please see attached the study protocol. We would be very grateful for your help in supporting this study. Should you have any queries regarding this please do not hesitate to contact us.

Kind regards

Dr. Annalisa Paviglianiti
Principal Investigator
Hôpital Saint-Antoine, Paris

Dr. Alberto Mussetti
Principal Investigator
Institut Català d'Oncologia, Barcelona

Pr. Bertram Glass
Chair
EBMT Lymphoma Working Party